Skip to Main Content

WASHINGTON — The Food and Drug Administration is working to increase its investment in reviewing gene therapy products, Commissioner Scott Gottlieb said Friday.

“We’re getting a hundred [new drug applications] a year for gene therapy products, and we’re going to have to very rapidly grow the size of the group to keep up with the pace of the inbox,” he said at an industry conference.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!